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 LVAD unloading reverses several but not all
aspects ofmyocardial remodelingandusually
leads to incomplete cardiac recovery in a
subset of patients with advanced HF.
 We performed metabolomic analysis and
mitochondrial structural and functional
characterization in paired human
myocardial tissue procured from
31 patients with advanced HF at LVAD
implant and at heart transplant plus
tissue from 11 normal donors.
 LVAD unloading induces glycolysis
up-regulation without a corresponding
increase in glucose oxidation.
 Lack of post-LVAD improvement in
mitochondrial function and volume
density could explain the
glycolysis-glucose oxidation mismatch.
 Therapeutic interventions, such as
myocardial conditioning, that are known
to improve mitochondrial biogenesis,
structure, and function might further
improve cardiac metabolism and energy
production and thereby enhance cardiac
recovery with LVAD-induced unloading.University of Utah Health Sciences
, Salt Lake City, Utah; bMolecular
etabolism, Department of Medicine,
R E V I A T I O N S
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6 Diakos et al.
O C T O B E R 2 0 1 6 : 4 3 2 – 4 4 LVAD Unloading and Cardiac Metabolism
433SUMMARY
AB BAND ACRONYM S
GC-MS = gas chromatography–
mass spectroscopy
HF = heart failure
LV = left ventricular
LVAD = left ventricular assist
device
TCA = tricarboxylic acid
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MaThis study sought to investigate the effects of mechanical unloading on myocardial energetics and the metabolic
perturbation of heart failure (HF) in an effort to identify potential new therapeutic targets that could enhance the
unloading-induced cardiac recovery. The authors prospectively examined paired human myocardial tissue pro-
cured from 31 advanced HF patients at left ventricular assist device (LVAD) implant and at heart transplant plus
tissue from 11 normal donors. They identiﬁed increased post-LVAD glycolytic metabolites without a coordinate
increase in early, tricarboxylic acid (TCA) cycle intermediates. The increased pyruvate was not directed toward
the mitochondria and the TCA cycle for complete oxidation, but instead, was mainly converted to cytosolic
lactate. Increased nucleotide concentrations were present, potentially indicating increased ﬂux through the
pentose phosphate pathway. Evaluation of mitochondrial function and structure revealed a lack of post-LVAD
improvement in mitochondrial oxidative functional capacity, mitochondrial volume density, and deoxyribonucleic
acid content. Finally, post-LVAD unloading, amino acid levels were found to be increased and could represent a
compensatory mechanism and an alternative energy source that could fuel the TCA cycle by anaplerosis. In
summary, the authors report evidence that LVAD unloading induces glycolysis in concert with pyruvate mito-
chondrial oxidation mismatch, most likely as a result of persistent mitochondrial dysfunction. These ﬁndings
suggest that interventions known to improvemitochondrial biogenesis, structure, and function, such as controlled
cardiac reloading and conditioning, warrant further investigation to enhance unloading-induced reverse
remodeling and cardiac recovery. (J Am Coll Cardiol Basic Trans Science 2016;1:432–44)
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).H eart failure (HF) is a global epidemic witha prevalence of 2% to 3% in the UnitedStates and Europe, and it is a huge cost to
the health care systems (1). Despite advances in phar-
macological therapies, implantable deﬁbrillators,
cardiac resynchronization, and stem cell/regenerative
therapies, patients with advanced HF experi-
ence mortality rates in excess of 50% per year (1).SEE PAGE 445Mechanical unloading through a left ventricular
assist device (LVAD) is a therapeutic intervention
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434We have previously shown that LVAD unloading
may lead to hypertrophy regression through disrup-
tion of the equilibrium between protein synthesis and
degradation (8). This altered equilibrium could also
affect the intracellular pool of amino acids. An
elevation in amino acid levels could provide alterna-
tive building blocks for protein synthesis and could
supplement the Krebs tricarboxylic acid (TCA) cycle
with intermediates through anaplerosis. Up-
regulation of anaplerosis has previously been shown
to play a cardioprotective role in the failing heart (9).
In this study we investigate how the mechanical
unloading induced by LVAD affects the bioenergetic
adaptation and metabolic perturbation in the chron-
ically failing human heart.
METHODS
STUDY POPULATION. We prospectively enrolled 31
consecutive patients with clinical characteristics
consistent with dilated cardiomyopathy and chronic
advanced HF who required circulatory support with
continuous ﬂow LVAD as bridge to transplantation.
Patients who required LVAD support due to acute HF
(acute myocardial infarction, acute myocarditis, post-
cardiotomy cardiogenic shock, and so on) were pro-
spectively excluded. Eleven normal donor hearts, not
allocated for heart transplantation due to noncardiac
reasons (size, infection, and so on) were used as
normal controls. The study was approved by the
institutional review board of the participating in-
stitutions, and informed consent was provided by all
patients (see the Supplemental Appendix for details).
MYOCARDIAL TISSUE ACQUISITION. Myocardial tis-
suewas prospectively collected from the LV apical core
at LVAD implantation. At the time of cardiac trans-
plantation, the tissue was obtained from the apex at
least 1.5 to 2 cm distant from the LVAD inﬂow cannula
site to avoid any reactive foreign body inﬂammatory
changes. Control samples were acquired from hearts
that were not transplanted due to noncardiac reasons.
Normal donor LV apical tissue was harvested and
processed the same way as the failing hearts.
METABOLOMIC ANALYSIS. The levels of metabo-
lites in the cardiac tissue were measured by gas
chromatography–mass spectroscopy (GC-MS) anal-
ysis. For details about tissue extraction and GC-MS
analysis, please see the Supplemental Appendix.
ELECTRON MICROSCOPY. Epon-embedded tissue
blocks were subject to ultramicrotomy and osmium/
uranyl acetate–based staining for electron micro-
scopy. Imaging was performed on a JEM 1010 electron
microscope (Jeol, Peabody, Massachusetts). A total of5 optical ﬁelds/heart were examined at 11,000
magniﬁcation. The number of mitochondria in each
size range was calculated as the percentage of
the total mitochondria count on the same amount
of area in each representative sampling. Mitochondria
volume density was estimated as previously
described (10).
RELATIVE MITOCHONDRIAL DEOXYRIBONUCLEIC
ACID LEVELS. The mitochondrial deoxyribonucleic
acid (DNA) content was quantiﬁed with real-time
polymerase chain reaction using SYBR Green PCR
master mix (Thermo Fisher Scientiﬁc, Waltham,
Massachusetts) and the primers that targeted a stable
site in mitochondrial DNA minimal arc and single-
copy nuclear DNA within the b2M gene (11). The
relative mitochondrial DNA content was calculated
from the ratio of mitochondrial DNA copy number to
nuclear DNA copy number, and the relative fold
change was normalized to normal donors (nonfailing
heart) using the DDCT method (see the Supplemental
Appendix for details).
MITOCHONDRIAL RESPIRATORY FLUX. Mitochondrial
respiration was assessed as previously described (12).
For details, please see the Supplemental Appendix.
STATISTICAL ANALYSIS. Statistical analysis was
performed as previously described (8,13). Values are
expressed as mean  SEM. The paired samples
Student t test was used for comparisons between pre-
and post-LVAD unloading. The independent samples
t test was used for comparisons between the failing
and the normal hearts. Prism 6 (GraphPad, San Diego,
California) was used for statistical analysis. Signiﬁ-
cance was determined as p < 0.05.
RESULTS
STUDY POPULATION AND HEMODYNAMIC DATA. The
clinical characteristics of the study population are
presented in Table 1. Hemodynamic data before and 2
months after LVAD implantation are shown in Table 2.
Left- and right-sided ﬁlling pressures were decreased
after LVAD implantation, indicating that LVAD effec-
tively induces left and right ventricular unloading. The
duration of LVAD support was 243  29.8 days.
METABOLOMIC DATA. A total of 30 paired myocar-
dial tissue samples obtained at the time of LVAD
implantation and again at the time of heart trans-
plantation together with 11 nonfailing heart samples
were examined with GC-MS. Figure 1 depicts the
GC-MS ﬁndings of a representative myocardial sam-
ple before and after LVAD unloading.
GLYCOLYSIS, KREBS (TCA) CYCLE INTERMEDIATES,
AND ANAPLEROSIS. Glucose-1-phosphate, which is a
TABLE 1 Baseline Clinical Characteristics of the Study
Population Before LVAD Implantation (N ¼ 31)
Men 30 (97)
Age, yrs 48  2
Etiology
Ischemic cardiomyopathy 11 (35)
Nonischemic cardiomyopathy 20 (65)
New York Heart Association functional class
III 10 (32)
IV 21 (68)
Duration of heart failure history, yrs 5.2  0.6
Systolic arterial pressure, mm Hg 97.0  1.5
Diastolic arterial pressure, mm Hg 66.0  1.4
Serum concentrations
Brain natriuretic peptide, pg/ml 1,568  157
Creatinine, mg/dl 1.40  0.05
Sodium, mmol/l 133.0  0.7
Hemoglobin, g/dl 12.1  0.3
Values are n (percentile of the total population) or mean  SEM.
LVAD ¼ left ventricular assist device.
TABLE 2 Hemodynamic Measurements Before and 2 Months After
LVAD Implantation (N ¼ 16)*
Before LVAD
Implantation
2 Months After LVAD
Implantation p Value
Mean right atrial, mm Hg 12.5  1.4 8.6  1.1 0.007
Pulmonary capillary wedge, mm Hg 25.0  2.4 12.0  1.6 0.0002
Systolic pulmonary arterial, mm Hg 53.6  3.8 37.5  3.1 0.001
Diastolic pulmonary arterial, mm Hg 28.3  2.3 14.7  1.1 <0.0001
Pulmonary vascular resistance, Woods Units 4.1  0.6 2.8  0.4 0.03
Cardiac index, l$m2$min1 1.9  0.2 2.4  0.2 0.046
Values are mean  SEM. *Right heart catheterization at 2 months post-implant was not performed in patients
that had thrombotic or bleeding complications or difﬁculties with their anticoagulation management.
LVAD ¼ left ventricular assist device.
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435product of glycogenolysis, increased after LVAD
unloading (9.12  2.60 vs. 2.47  0.56; p ¼ 0.02),
suggesting increased utilization of glycogen during
mechanical unloading (Figure 2). Glucose-6 phos-
phate, which is the product of the ﬁrst reaction of
glycolysis, increased after LVAD unloading (29.68 
11.00 vs. 5.55  0.87; p ¼ 0.04) (Figure 2). Along the
same pathway, pyruvate (the ﬁnal product of gly-
colysis before mitochondrial oxidation) was also
increased post-LVAD (39.4  4.0 vs. 20.1  2.0;
p < 0.0001), suggesting a glycolytic shift during
LVAD-induced mechanical unloading. Post-LVAD
pyruvate levels were also signiﬁcantly higher rela-
tive to the normal donor heart (39.4  4.0 vs. 21.6 
4.0; p ¼ 0.013) (Figure 2). Interestingly, we observed
increased post-LVAD levels of lactate relative to both
the pre-LVAD myocardial tissue sample (1,509 
112 vs. 665  52; p < 0.0001) and the normal donor
heart (1,509  112 vs. 1,010  269; p ¼ 0.049) (Figure 2).
The early Krebs (TCA) cycle intermediates, that is,
citrate and a-ketoglutarate, were decreased in failing
hearts compared with normal donor hearts (2,804 
361 vs. 5,989  2,355; p ¼ 0.04; and 0.40  0.06 vs.
0.70  0.14; p ¼ 0.008) (Figure 3). Interestingly,
despite increased pyruvate post-LVAD, these TCA
cycle intermediates remained at low levels after
LVAD unloading. Taken together, these ﬁndings
suggest increased glycolysis and a defect in mito-
chondrial oxidation leading to increased cytosolic
lactate rather than the increased pyruvate entering
the TCA cycle in the mitochondria.
By contrast, the subsequent TCA cycle inter-
mediates after the succinyl CoA anaplerotic accesspoint increased signiﬁcantly after LVAD unloading
(succinate: 941  84 vs. 225  25; p < 0.0001; fuma-
rate: 75.0  7.6 vs. 50.0  9.7; p ¼ 0.032; and malate:
225  25 vs. 101  12; p ¼ 0.0002) (Figure 3). These
ﬁndings suggest altered anaplerosis and cataplerosis
during LVAD mechanical unloading of the failing
human heart (Figure 3). Along the same lines, Figure 4
shows that most amino acids were decreased in the
failing human hearts compared with the normal
donor hearts, and after LVAD unloading, their levels
were restored or even further increased. Of note, the
amino acids isoleucine, methionine, and leucine that
are precursors for the TCA cycle anaplerotic entry
point at the level of succinyl CoA were markedly
elevated, even higher than the levels of the normal
donor hearts (Figure 4). In addition, phenylalanine
and tyrosine, which are precursors for the TCA cycle
anaplerotic entry point at the level of fumarate, were
also signiﬁcantly elevated during LVAD mechanical
unloading (Figure 4).
MITOCHONDRIA OXIDATIVE PHOSPHORYLATION
CAPACITY. To investigate the alterations of mito-
chondrial function between nonfailing donor hearts
and advanced failing hearts before and after LVAD
unloading, we assessed mitochondrial respiratory
ﬂux of the collected myocardial tissue. State 3 com-
plex I and state 3 complex I þ II respiration demon-
strated a signiﬁcant reduction in the failing human
heart before LVAD implantation relative to normal
donor hearts; however, the state 2 showed no signif-
icant difference among all the groups (Figure 5). State
3 complex I and state 3 complex I þ II respiration were
unchanged after LVAD unloading (Figure 5). The res-
piratory control ratio and maximum respiration
induced by TMPD and ascobate (complex IV) were
also signiﬁcantly higher in normal donor hearts than
in the failing human hearts before and after LVAD
unloading (Figure 5). The respiratory control ratio was
4.7  0.5 for normal donor hearts, and 3.4  0.8 and
FIGURE 1 Gas Chromatography–Mass Spectroscopy of a Representative Myocardial Sample Before and After LVAD Unloading
(Top) Before left ventricular assist device (LVAD) unloading (red); (bottom) after LVAD unloading (green). The insets show the area under the
curve ratio of metabolite signals at pre- (pink) and post-LVAD (green) time points. The glycolysis intermediates glucose-6-phosphate (G6P),
pyruvate, and lactate increased signiﬁcantly post-LVAD. Similarly, the branched chain amino acids leucine (leu) and isoleucine (ile) also
increased in the post-LVAD unloading sample.
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respectively. Thus LVAD-induced mechanical un-
loading did not reverse the impaired oxidative ca-
pacity of the mitochondria of the failing human heart.
MITOCHONDRIA DENSITY AND STRUCTURE. Mito-
chondrial volume density in failing hearts, assessed
by electron microscopy, was reduced compared with
the normal heart (Figures 6A to 6C). Consistent with
this observation, mitochondrial DNA content was also
found to be decreased in the failing heart compared
with the normal donor hearts (Figure 6D). The mito-
chondria volume density and mitochondrial DNA
levels were not signiﬁcantly altered during LVAD
unloading (Figures 6A to 6D). Moreover, the ultra-
structural morphology (as assessed by electron
microscopy) revealed that cardiac mitochondria atthe time of LVAD implant were smaller (Figure 6E)
and characterized by disorganized cristae and
decreased matrix density versus those of normal
donor hearts. However, mitochondria after LVAD
unloading consistently revealed signiﬁcant but vari-
able improvements in some of these speciﬁc
morphological characteristics (Figures 6A, 6B, and 6E).
We did not have enough subjects to adequately
explore whether the subgroup of patients with sig-
niﬁcant myocardial functional improvement after
LVAD unloading (i.e., cardiac recovery “responders”)
exhibited improved mitochondrial oxidative capacity
and increased mitochondrial density and DNA con-
tent to a greater extent than the cardiac recovery
“nonresponders.” However, our limited data did
show a trend toward greater mitochondrial improve-
ment in the patients with the greatest favorable
FIGURE 2 Glycolytic Metabolites in the Nonfailing Donor Heart and the Failing Heart
Before and After LVAD Unloading
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437cardiac functional and structural response after LVAD
mechanical unloading (data not shown).
NUCLEIC ACIDS. To assess changes in DNA synthesis
with LVAD therapy, purines and pyrimidines were
measured in the myocardial samples. Cardiac levels
of the purine intermediates, xanthine and hypoxan-
thine, were increased after LVAD unloading (2.8 
0.5 vs. 0.8  0.2; p < 0.0001; and 128  17 vs. 31  4;
p < 0.0001, respectively) (Figure 7). Similarly, uracil, a
pyrimidine product, was also elevated after LVAD
unloading (2.5  0.2 vs. 1.3  0.2; p < 0.0001). Finally,
adenosine levels increased post-LVAD unloading and
reached the levels of the normal heart (561  77 vs.
116  21; p < 0.0001).
DISCUSSION
Our report integrates static and dynamic/functional
cardiac metabolism studies performed in a large
number of paired human myocardial tissue samples.
Our ﬁndings indicate a post-LVAD induction of all
measured glycolytic metabolites, including pyruvate,
but without a corresponding increase in the initial
intermediates in the Krebs cycle. This ﬁnding, in
combination with the post-LVAD increased lactate
levels, is consistent with decreased mitochondrial
utilization of pyruvate generated from enhanced
glycolysis leading to increased cytosolic lactate. Thus
the post-LVAD heart is associated with a glycolysis-
pyruvate mitochondrial oxidation “mismatch.” This
conclusion is supported by our evaluation of
mitochondrial function and structure: 1) the lack of
post-LVAD improvement in mitochondrial oxidative
capacity of the failing human heart; and 2) the persis-
tent reduction in mitochondrial volume density and
DNA content. We did not have an adequate number of
subjects to perform a robust subgroup analysis to
convincingly address whether the smaller subgroup of
patients with HF who had improved cardiac function
and structure after LVAD unloading (i.e., cardiac
recovery responders) might exhibit improved mito-
chondrial function and structure. However, our
preliminary data did show a trend toward such mito-
chondrial improvement in the patients with the
greater cardiac functional and structural response
after LVAD mechanical unloading. Furthermore, the
ultrastructural morphology as assessed with electron
microscopy revealed that compared with the normal
donor heart, cardiac mitochondria at the pre-LVAD
time point had smaller size, disorganized cristae, and
decreased matrix density, whereas the mitochondria
after LVAD unloading consistently showed signiﬁcant
improvement in these speciﬁc morphological charac-
teristics. Together, these ﬁndings suggest that LVAD
FIGURE 3 Krebs (TCA) Cycle Intermediates
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438support induces myocardial “remission” rather than
complete myocardial recovery. Importantly, demon-
stration of mitochondrial “health” could be used as a
“signature” of true recovery. Furthermore, therapeu-
tic interventions, such as myocardial conditioning,
that are known to improve mitochondrial biogenesis,
structure, and function might be useful to further
improve cardiac metabolism and energy production
and thereby enhance myocardial reverse remodeling
and cardiac recovery with LVAD-facilitated mechani-
cal unloading.
We also found increased levels of amino acids
following LVAD implantation. Amino acids can serveas an alternative energy source by supplying the
Krebs cycle with intermediate metabolites through
the anaplerosis cycle. Indeed, we found speciﬁc in-
termediate metabolites at the Krebs cycle anaplerosis
entry points to be signiﬁcantly increased post-LVAD
unloading. These post-LVAD increased nucleic
amino acids could play an important role as alterna-
tive building blocks for protein synthesis and
cellular biogenesis to facilitate LVAD-induced
reverse remodeling of the failing human heart. Also,
these increased nucleotide concentrations could
potentially indicate increased ﬂux through the
pentose phosphate pathway.
FIGURE 4 Amino Acids Were Decreased in the Failing Human Heart Compared With the Normal Heart
Iso
leu
cin
e
Le
uc
ine
Me
thi
on
ine
Ph
en
yla
lan
ine
Ty
ros
ine
Hi
sti
din
e
Pr
oli
ne
Tr
yp
top
ha
n
Th
reo
nin
e
Ala
nin
e
Ho
mo
se
rin
e
0
20
40
60
80
100
200
400
600
800
R
el
at
iv
e
le
ve
l o
f n
or
m
al
iz
ed
 a
m
in
o 
ac
id
s
Normal Donors
Pre-LVAD
Post-LVAD
*,#
*,#
*,##
*
#
* *
#
*
*
*,#
#
*
*
#
Left ventricular assist device (LVAD) unloading restored amino acid levels. #Signiﬁcant difference in comparison to the normal donor heart;
p < 0.05. *Signiﬁcant difference in comparison to the pre-LVAD time point; p < 0.05.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6 Diakos et al.
O C T O B E R 2 0 1 6 : 4 3 2 – 4 4 LVAD Unloading and Cardiac Metabolism
439GLYCOLYSIS-PYRUVATE MITOCHONDRIAL OXIDATION
MISMATCH. Glucose represents amore efﬁcient energy
source requiring less oxygen consumption per unit of
adenosine triphosphate (ATP) generated relative to
fatty acids (14,15). Positron emission tomography
studies have shown increased glucose and decreased
fatty acid uptake from the failing heart, suggesting
that glucose is the main metabolic substrate of the
failing heart, whereas the normal heart relies more on
fatty acids (16). Whether this “metabolic switch” from
fatty acids to glucose plays a beneﬁcial or detrimental
role in the progression of the disease and whether
LVAD unloading could favorably affect the metabolic
phenotype of the failing heart is a matter of investi-
gation (17). Weitzel et al. (18) investigated 8 patients
with LVADs and showed that both glucose and lactate
are reduced in the failing compared with the normal
heart and that LVAD unloading restored their levels. Of
note, that study did not investigate the response of
glucose oxidation after mechanical unloading. Animal
and human data from 2 recently published studies
from Aubert et al. (19) and Bedi Jr. et al. (20) showed
decreased levels of TCA cycle intermediates with par-
allel up-regulation of ketone oxidation in the failing
heart. In agreement with the aforementioned studies,
we observed a signiﬁcant reduction of metabolites
involved in glycolysis and glucose oxidation in the
failing heart at the pre-LVAD implantation time point.This metabolic pattern combined with the reduced
levels of other metabolic substrates (i.e., fatty acid and
amino acids) and the decreased oxidative phosphory-
lation capacity represent a decreased metabolic state
consistent with severe energetic impairment of the
failing heart (5).
The failing heart is characterized by impaired
mitochondrial biogenesis, as well as structural and
functional mitochondrial defects (21,22). A recent
study from Cordero-Reyes et al. (23) surprisingly
showed that isolated mitochondria from failing hu-
man hearts demonstrate preserved respiration; the
authors concluded that impaired energy metabolism
of the failing heart might be due to decreased mito-
chondria number or defects in substrate delivery. In
another study by Scheubel et al. (24), decreased
complex I activity of the failing human heart was not
associated with mitochondrial DNA damage or sup-
pressed mitochondrial gene expression. The absence
of mitochondrial DNA defects could serve as a good
prognostic factor, providing the mitochondria of the
failing human heart with the potential of recovery
under appropriate therapeutic interventions (24).
Whether LVAD unloading could lead to improvement
of mitochondrial function is a matter of controversy.
Lee et al. (25) have shown improved state 2 and 4
mitochondrial respiration of the unloaded compared
with the nonunloaded failing heart. By contrast, Mital
FIGURE 5 Oxidative Function of Mitochondria in the Nonfailing Donor Heart and in the Advanced Failing Heart at Pre- and Post-LVAD
Unloading Time Points
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Complex I, complex I þ II, and complex IV respiration of isolated permeabilized myoﬁbers from failing hearts was signiﬁcantly lower compared
with the nonfailing heart. Mitochondrial oxidative capacity remained signiﬁcantly reduced after left ventricular assist device (LVAD) unloading.
*p < 0.05; **p < 0.01; ***p < 0.001.
Diakos et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6
LVAD Unloading and Cardiac Metabolism O C T O B E R 2 0 1 6 : 4 3 2 – 4 4
440et al. (26) did not observe differences in the baseline
mitochondrial respiration, but the mitochondria of
the unloaded heart had a favorable response to NO.
These studies are limited by the absence of control
normal hearts and by the fact that the comparisons of
mitochondrial function were not made with paired
pre- and post-LVAD myocardial tissue samples but
were instead between unloaded and nonunloaded
hearts from different patients.
In our study, we also found evidence indicating a
post-LVAD glycolysis-pyruvate oxidation mismatch.
Although glycolysis was induced after LVAD unload-
ing leading to increased pyruvate production, the
latter was not directed into the TCA cycle and the
mitochondria for complete oxidation. Instead, we
provided evidence that the pyruvate was converted
into lactic acid in the cytoplasm. This phenomenon
might be explained by the decreased energy demands
of the unloaded heart that makes glycolysis a sufﬁ-
cient energy source to cover ATP requirements. Also,
because intramitochondrial glucose oxidation is the
major source for reactive oxygen species production
in the respiratory chain, the observed glycolysis-
pyruvate oxidation mismatch could represent a pro-
tective mechanism leading to oxidative stress
reduction.
AMINO ACIDS, ANAPLEROSIS, AND INTERACTIONS
WITH THE TCA CYCLE AND MYOCARDIAL REPAIR
MECHANISMS. A transcriptomic analysis by Lai et al.(27) showed a reduction in the expression of a subset
of genes involved in amino acid degradation in the
failing heart. We did not observe elevated levels of
amino acids in the failing human heart before LVAD
unloading compared with the normal heart. However,
we identiﬁed increased levels of amino acids after
LVAD unloading. We hypothesize that amino acids
may serve as an alternative energy source by sup-
plying the TCA cycle with metabolic intermediates
through anaplerosis. The balance of anaplerosis and
cataplerosis is essential for the function of the TCA
cycle, but the effect of changes in the anaplerosis/
cataplerosis ﬂux in the energetic and metabolic
adaptations of chronic HF and during mechanical
unloading is not well understood. The prevailing
view in cardiovascular disease is that increased
anaplerotic ﬂux might be beneﬁcial and may play an
important role in regulating bioenergetic adaptations
to ATP demand (28). Another collateral metabolic
pathway involving anaplerosis/catabolism is the
biosynthesis of building blocks (nonessential amino
acids, fatty acid, and nucleotides) necessary for repair
mechanisms of the failing heart. In support of this
hypothesis, we found increased nucleic acid levels,
which could be consistent with induction of nucleo-
tide synthesis or salvage pathways in the unloaded
heart (Figure 7). In addition to their putative role in
protein synthesis, we believe that amino acids
are also used as metabolic substrates in TCA cycle
FIGURE 6 Ultrastructural Morphology, Mitochondrial Volume Density, and Mitochondrial DNA Content in the Normal Donor Heart and in
the Failing Human Heart Before and After LVAD Unloading
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(A) Transmission electron microscopy photomicrographs depicting longitudinal rows of mitochondria located in parallel with the sarcomeres/
contractile apparatus. The magniﬁcation is 15,000, and the scale bar indicates the length of 2 mm. (B) Higher magniﬁcation of mitochondrial
ultrastructure at 50,000. Compared with the normal donor heart, the mitochondria at the pre-LVAD time point were smaller, had disor-
ganized cristae, and had decreased matrix density, whereas the mitochondria after LVAD unloading consistently showed improvement in these
speciﬁc morphological characteristics. The scale bar indicates the length of 1 mm. Mitochondrial volume density (C) and mitochondrial DNA
(mtDNA) content (D) were lower in the failing human heart compared with the nonfailing donor heart. mtDNA levels and volume density
remained unchanged after LVAD unloading. The number of large mitochondria in the normal control group were higher than the failing human
heart (E). The average size of mitochondria improved slightly after LVAD unloading. *Signiﬁcant difference in comparison to the normal donor
heart; p < 0.05. þSigniﬁcant difference in comparison to the pre-LVAD time point. Abbreviations as in Figure 2.
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441anaplerosis or by being transformed to fatty
acids through removal (cataplerosis) of TCA cycle
intermediates (29). In our study, we found increased
levels post-LVAD of succinate and of subsequent TCA
cycle intermediates such as fumarate and malate,
whereas preceding intermediates such as keto-
glutarate remained unaltered. These ﬁndings, inconjunction with the increased isoleucine and
methionine post-LVAD, suggest that succinate could
serve as the entry point of the increased amino acids
into the TCA cycle of the LVAD unloaded heart. Also,
elevated levels of fumarate, phenylalanine, and
tyrosine suggest that the deamination of phenylala-
nine and tyrosine to fumarate could be another entry
FIGURE 7 Nucleotide Levels in Normal Donor Heart and
Advanced Failing Heart Before and After LVAD Unloading
Ad
en
os
ine
Ur
ac
il
Xa
nth
ine
Hy
po
xa
nth
ine
0
2
4
6
8
10
200
400
600
800
R
el
at
iv
e 
le
ve
l o
f n
or
m
al
ize
d
nu
cl
eo
tid
es
*
#
*,# *,#
*#
Normal Donors
Pre-LVAD
Post-LVAD
The myocardial tissue post-LVAD unloading showed a signiﬁcant
increase in nucleotide levels. #Signiﬁcant difference in compari-
son to the normal donor heart; p < 0.05. *Signiﬁcant difference
in comparison to the pre-LVAD time point; p < 0.05.
Diakos et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6
LVAD Unloading and Cardiac Metabolism O C T O B E R 2 0 1 6 : 4 3 2 – 4 4
442point to the TCA cycle. Finally, elevated levels of
malate could be explained by either the conversion of
fumarate to malate through the TCA cycle or by the
up-regulation of the pyruvate-malate shuttle and the
subsequent conversion of pyruvate to malate (30).
The supplementation of the TCA cycle with in-
termediates ensures continued function of the cycle
and continued production of nicotinamide adenine
dinucleotide (NADH) that is directed to the respira-
tory chain for ATP production. Interestingly, we
observed a signiﬁcant increase of malate after LVAD
unloading. Malate plays an important role in cardiac
metabolism because it can be transformed to pyru-
vate and glucose, thereby augmenting glycolytic
metabolism via the malate/aspartate shuttle (31).
Increased activity of the shuttle leads to oxidation of
NADH to NADþ in the cytosol and transportation of
NADH in the mitochondria (32). Cytosolic NADþ is
important because it is used to promote glycolysis by
the transformation of glyceraldehyde-3-phosphate to
1,3-bisphosphoglyceraldehyde. Mitochondrial NADH
is led to the electron transport chain (ETC) for ATP
production. Thus, up-regulation of the malate/
aspartate shuttle ensures continued glycolysis and
NADH ﬂux to the electron transport chain for ATP
production.
MITOCHONDRIAL DENSITY AND FUNCTION, CARDIAC
RELOADING/CONDITIONING, AND CLINICAL RESEARCH
IMPLICATIONS. Our data indicate that the impairment
in mitochondrial density and function post-LVADcould represent an underlying mechanism for the
glycolysis-pyruvate oxidation mismatch by limiting
subsequent pyruvate oxidation. Furthermore, our
preliminary data also revealed that the subset of pa-
tients with the greater myocardial functional
response after LVAD mechanical unloading also
showed improved post-LVAD mitochondrial function
and structure. On the basis of our observations, in-
terventions that are known to further enhance mito-
chondria number, function, and structure could
promote the favorable cardiac functional and struc-
tural response indicative of myocardial recovery in
LVAD patients (4,33). Prior studies have shown that
exercise and conditioning promotes mitochondria
biogenesis and improves glucose metabolism (34,35).
Importantly, Kajimoto et al. (36) showed that
myocardial reloading after a period of unloading in-
creases TCA intermediates, suggesting increased
anaplerosis and mitochondrial oxidative capacity. On
the basis of these results, exercise and controlled
cardiac reloading could be additional therapeutic in-
terventions that could enhance LVAD-induced
reverse remodeling and myocardial recovery and
warrant further investigation. A controlled cardiac
reloading and myocardial conditioning strategy has
been recently attempted in LVAD patients by our
group and others with promising results (37,38).
STUDY LIMITATIONS. Our study design does not
allow multiple serial tissue evaluations. This could
have provided useful information about dynamic
changes of substrate utilization by the failing heart
during chronic mechanical unloading. Also, our
experimental setup did not allow us to measure in-
sulin resistance and myocardial glucose uptake.
These measurements might have provided useful
information as to whether the induction of glycol-
ysis is secondary to increased glucose uptake or to
increased activity of glycolytic enzymes. Finally, our
data represent static metabolic measurements at the
pre- and post-LVAD unloading time points. Thus,
conclusions regarding dynamic metabolic changes
should be made cautiously. Future pulse chase
studies with stable isotope-labeled metabolites are
warranted to conﬁrm the metabolic intracellular
ﬂux.
CONCLUSIONS
LVAD-induced mechanical unloading of the failing
human heart induces up-regulation of the glycolysis
without a parallel increase in pyruvate utilization
for mitochondrial oxidation. Amino acid levels
increased signiﬁcantly during LVAD unloading,
potentially acting as a compensatory mechanism and
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Mechanical
unloading reverses several, but not all, aspects of myocardial
remodeling. Our study describes increased post-LVAD glycolysis,
but reduced mitochondrial density and suppressed mitochondrial
function, in the failing human heart that is not corrected by LVAD
unloading. The identiﬁcation of nonreversible features of cardiac
remodeling could guide the application of adjunct pharmaco-
logical or other physiological interventions in an effort to
enhance unloading induced cardiac recovery. Furthermore,
demonstration of mitochondrial “health” could be used a
“signature” of true recovery.
TRANSLATIONAL OUTLOOK: The described persistent
mitochondrial defect might be the underlying cause of the lim-
itations observed with LVAD-induced myocardial recovery. The
next important step will be to determine whether therapeutic
interventions, such as myocardial conditioning and controlled
cardiac reloading, that are known to improve mitochondrial
biogenesis, structure, and function will enhance the favorable
cardiac functional response in the patient with an LVAD.
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443an alternative energy source through the TCA cycle
anaplerosis entry points while also serving as
potential building blocks for cardiac repair. The
reduced mitochondrial density, structure, and
function after LVAD unloading could represent a
potential mechanism for the glycolysis-pyruvate
oxidation mismatch and could provide a signature
for myocardial recovery. Therefore, interventions
that enhance mitochondrial biogenesis, function,
and structure, such as exercise and controlled
cardiac reloading and conditioning, should be
further investigated as a strategy that may enhance
LVAD-induced myocardial reverse remodeling and
cardiac recovery.
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